Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPeR Study
2012-004888-41Phase 3Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Phoscat in chronic kidney disease (CKD) and hyperphosphatemia (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Composite of all-cause death or initiation of dialysis. Started Dec 2012; status: completed.
02
Drugs
Phoscat
03
Conditions
chronic kidney disease (CKD)hyperphosphatemia
Beyond the preview
Go deeper on 2012-004888-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004888-41.